Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Manojkumar Bupathi
Managing Diarrhea and Optimizing Dose Reductions With NALIRIFOX
Diarrhea remains a primary distinguishing toxicity associated with NALIRIFOX (liposomal irinotecan [Onivyde], oxaliplatin, fluorouracil, and leucovorin) relative to other frontline regimens for metastatic pancreatic cancer. Managing it effectively can determine whether a patient stays on treatment long enough to derive benefit. In the phase 3 NAPOLI-3 trial (NCT04083235), more than half of patients receiving liposomal irinotecan required some type of dose reduction.
County-Level Medical Debt Tied to Later-Stage Cancer Diagnosis, Worse Survival
Patients with cancer living in US counties with the highest share of residents carrying medical debt in collections were more likely to be diagnosed with stage IV disease and had worse overall survival (OS) than those in counties with the lowest debt burden, according to a study published in the Journal of the National Comprehensive Cancer Network (JNCCN).1 The analysis, led by researchers at the American Cancer Society (ACS), linked National Cancer Database (NCDB) records for more than 7.5...
Making Nuanced Decisions on CAR-T and Bispecifics in Multiple Myeloma
In a CancerNetwork® Face-Off event, experts in the multiple myeloma field divided into 2 teams to discuss the efficacy, safety, and real-world considerations surrounding different cellular therapy modalities. The conversation focused on how CAR T-cell therapies in trials like the phase 3 CARTITUDE-4 study (NCT04181827) compare with bispecific antibodies, which have been evaluated in trials like the phase 3 MajesTEC-3 study (NCT05083169).
What Role Will Artificial Intelligence Play in Genitourinary Oncology?
In the newest episode of Oncology Decoded, hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, spoke about the implementation of artificial intelligence (AI)–based tools and large language models (LLMs) into the study and management of genitourinary malignancies. Leveraging his background in biomedical informatics, Bupathi broke down the specific tools that can assist with documentation, digital pathology, real-time diagnostics, and other relevant clinical applications.
01 Real-World Outcomes of Radiation Omission After Breast-Conserving Surgery in Older Women With Stage I ER-Positive Breast Cancer: A SEER Analysis (2000–2022)
Background Randomized trials support the omission of radiation therapy (RT) after breast-conserving surgery (BCS) in selected older women with early-stage estrogen receptor (ER)–positive breast cancer. However, the real-world adoption and long-term outcomes of RT omission in population-based practice remain incompletely characterized. Materials and Methods Using the Surveillance, Epidemiology, and End Results database, we carried out population-based cohort research from 2000 to 2022.
OS Does Not Improve With Continuous Vs Fixed Lenalidomide Dosing in NDMM
Indefinite-duration or continuous lenalidomide (Revlimid) maintenance did not significantly improve overall survival (OS) compared with a fixed 2-year duration in patients with standard-risk newly diagnosed multiple myeloma (NDMM) who were not undergoing up-front autologous stem cell transplantation (ASCT), according to findings from the phase 3 ENDURANCE (E1A11) trial (NCT01863550) published in The New England Journal of Medicine.¹ The results suggest that a defined 2-year course of...
Mitigating Stomatitis and Optimizing Gedatolisib Treatment in Breast Cancer
With the FDA approval of the multi-target PAM inhibitor gedatolisib (Revtorpyk) for hormone receptor–positive, HER2-negative metastatic breast cancer, proper adverse effect (AE) mitigation has become a primary focus for oncology care teams.1 Among the key safety parameters identified in the phase 3 VIKTORIA-1 trial (NCT05501886), stomatitis emerged as a notable AE requiring proactive clinical intervention.2 Sara Hurvitz, MD, FACP, broke down the historical context and modern strategies for...
Sequencing Treatment after EV-Pembro in Urothelial Carcinoma
In this episode of Oncology Decoded, hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discussed treatment for urothelial carcinoma following updates from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) now the frontline standard, the hosts focused on emerging biomarker-driven strategies that show efficacy after progression on first-line care.
HSD112 REAL-WORLD PATTERNS OF HOMOLOGOUS RECOMBINATION REPAIR TESTING OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC) IN THE US COMMUNITY ONCOLOGY SETTING
Cookie Preference Center We use cookies which are necessary to make our site work. We may also use additional cookies to analyse, improve and personalise our content and your digital experience. For more information, see our Cookie Policy and the list of Google Ad-Tech Vendors. You may choose not to allow some types of cookies. However, blocking some types may impact your experience of our site and the services we are able to offer.
Where Do Bispecific Antibodies Stand in the Follicular Lymphoma Landscape?
Investigators are working to elucidate the role of bispecific antibodies in the follicular lymphoma landscape and if chemotherapy-free regimens could be feasible for these patients.
A Death Doula on Pancreatic Cancer and the Limits of a TV Portrayal
Kim Stravers is a certified end-of-life doula and educator with the International End of Life Doula Association (INELDA), with additional proficiency through the National End-of-Life Doula Alliance (NEDA). She is based in the Phoenix, Arizona area, volunteers with a local hospice organization, and provides private doula services to patients navigating serious illness and their circles of care.
Tafasitamab Combo Receives Japanese Approval for Relapsed/Refractory DLBCL
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the combination of tafasitamab-cxix (Monjuvi) plus lenalidomide (Revlimid) for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to a news release from the developer, Incyte Biosciences Japan G.K.1 Supporting the Japanese regulatory decision were findings from the phase 2 MOR208C203/L-MIND trial (NCT02399085) and the phase 1b/2 INCMOR 0208-102/J-MIND trial...
VS-7375 Exhibits Activity in KRAS G12D–Mutated Solid Tumors
VS-7375, an investigational oral KRAS G12D (ON/OFF) inhibitor, demonstrated encouraging clinical activity and a favorable safety and tolerability profile across multiple dose levels and tumor types in the ongoing phase 1/2 TARGET-D 101 trial (NCT07020221), according to a news release from Verastem Oncology.1 Activity was observed in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), metastatic colorectal cancer (CRC), and advanced non–small cell lung cancer (NSCLC), both as...
GLP-1s in Breast Cancer: Overall Survival, Recurrence Risk, and Safety
As more patients with breast cancer inquire about using GLP-1 receptor agonists to manage treatment-related weight gain, clinicians must look closely at long-term safety and survival data. Sherry Shen, MD, highlighted promising data from recent database studies indicating a strong signal toward improved overall survival.
ASCO 2026: Practice-Guiding Updates in Bladder and Kidney Cancer
In the newest episode of Oncology Decoded, hosts Manojkumar Bupathi, MD, MS; and Benjamin Garmezy, MD, discussed takeaways from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting that may guide clinical practice. Following their initial conversation on the most critical presentations in prostate cancer, Bupathi and Garmezy spoke about additional presentations that may influence decision-making in the clinic for patients with bladder cancer and kidney cancer.
74 Real-World Study Characterizing Patient Characteristics, Treatments, and Unmet Need in IO-Ineligible Patients With Metastatic Triple-Negative Breast Cancer
Background Metastatic triple-negative breast cancer (mTNBC) is the most aggressive breast cancer subtype, with an estimated 15% five-year survival rate. Immunotherapy (IO) has demonstrated substantial anticancer effects, particularly in tumors overexpressing PD-L1. However, up to 70% of patients with previously untreated mTNBC may not be candidates for IO. Limited real-world (rw) evidence exists characterizing treatment patterns and clinical outcomes among these patients.
Fixed-Duration Epcoritamab Combo Shows Superiority in Follicular Lymphoma
The addition of fixed-duration epcoritamab-bysp (Epkinly) to lenalidomide (Revlimid) and rituximab (Rituxan) exhibited superior outcomes vs lenalidomide/rituximab alone across key subgroups as a treatment for patients with relapsed/refractory follicular lymphoma (FL) previously treated with at least 1 prior therapy, including an anti-CD20 monoclonal antibody plus an alkylating agent, according to findings from a subgroup analysis of the phase 3 EPCORE FL-1 trial (NCT05409066) presented at the...
Tisa-Cel Yields Enduring Remissions in Younger High-Risk B-ALL Population
Tisagenlecleucel (tisa-cel; Kymriah) produced durable remissions among pediatric and young adult patients with high-risk B-cell acute lymphoblastic leukemia (B-ALL) and minimal residual disease (MRD) following frontline consolidation therapy, according to a presentation on findings from the phase 2 CASSIOPEIA/COG AALL1721 trial (NCT03876769) at the European Hematology Association (EHA) 2026 Congress.1 The estimated overall survival (OS) rate at 4 years was 85% (95% CI, 76%-90%), which...
VT-EBV-N Yields Durable Disease-Free Survival in Pretreated ENKTL
VT-EBV-N displayed durable disease-free survival (DFS) compared with plasma blood mononuclear cell (PBMC) therapy among patients with Epstein-Barr virus (EBV)–positive extranodal natural killer (NK)/T-cell lymphoma (ENKTL)who experienced a complete remission (CR) within 6 months prior to enrollment, according to an oral presentation of a phase 2 study (NCT03671850) presented at the European Hematology Association (EHA) 2026 Congress.1 Findings from the study demonstrated a significant DFS...
Anbenitamab Regimen Meets Phase 3 End Points in HER2+ Breast Cancer
Results from a phase 3 clinical trial evaluating anbenitamab (KN026; Ennituo) plus docetaxel for injection albumin-bound (HB1801) in patients with HER2-positive breast cancer met the prespecified primary end point of progression-free survival (PFS) assessed by the independent data monitoring committee, according to a press release from the developer, CSPC Pharmaceutical Group Limited.1 In the phase 3 HEALER or KN026-003 trial (NCT05838066), investigators plan to enroll approximately 880...
ASCO 2026: Translating the Top Prostate Cancer Data Into Clinical Action
In the newest episode of Oncology Decoded, hosts Manojkumar Bupathi, MD, MS; and Benjamin Garmezy, MD, provided a recap of the most critical presentations and data to emerge from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Specifically, they highlighted the late-breaking abstracts that may transform the standard of care for different prostate cancer populations.
ASCO 2026: Real-World Characteristics, HRR Mutation Testing, Treatment Patterns, and Outcomes of Patients with mCSPC in the US Community Oncology Setting
(UroToday.com) The 2026 American Society of Clinical Oncology Genitourinary (ASCO) Annual Meeting, held in Chicago, IL, will host the Prostate, Testicular, and Penile Cancer – Posters Session. Dr. Manojkumar Bupathi will present Abstract 5080: Real-world characteristics, HRR mutation testing, treatment patterns, and outcomes of patients with metastatic castration sensitive prostate cancer (mCSPC) in the US community oncology setting.
Breaking Silos: The Vital Role of Oncology Training Programs in Lymphoma
The landscape of oncology has shifted toward a collaborative model where academic silos are no longer viable. According to Hua-Jay Cherng, MD, assistant professor of medicine in the Lymphoma Program in the Division of Hematology and Oncology at Columbia University Irving Medical Center, who spoke with CancerNetwork® at Columbia University, organizations such as the Academy of Next Wave of Investigators and the ASH Clinical Research Training Institute play a pivotal role in this transition.
Optimizing Therapeutic Strategies Across the NMIBC Paradigm
In the newest episode of Oncology Decoded, hosts Manojkumar Bupathi, MD, MS; and Benjamin Garmezy, MD, convened with their colleagues Suzanne B. Merrill, MD, FACS; and Mark D. Tyson II, MD, MPH. They broke down the current treatment paradigm for those with non–muscle-invasive bladder cancer (NMIBC) by discussing how novel therapeutic modalities, patient selection criteria, and other practical considerations fit into effective clinical strategies.
Novel Drug Class is Convenient and Meaningful in Multiple Myeloma Landscape
In a conversation with CancerNetwork®, Shebli Atrash, MD, discussed how novel CELMoDs may impact the treatment paradigm for patients with multiple myeloma. He noted how these agents appear to be more potent and active in refractory diseases compared with previously developed immunomodulatory drugs.
Orca-T May Be “Important Step Forward” in Hematologic Malignancy Care
In October 2025, the FDA granted priority review to Orca-T as a treatment for patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS) undergoing hematopoietic stem cell transplantation.1 The agency is currently evaluating the biologics license application for Orca-T after extending its review period in light of newly submitted chemistry, manufacturing, and controls data.2 Ahead of the potential approval, CancerNetwork® spoke with...
Utilizing AI Algorithms to Inform Breast Cancer Chemoprevention Strategies
In the clinical setting, determining the most effective path for breast cancer risk reduction requires a nuanced, data-driven approach. Elizabeth Mittendorf, MD, highlighted how advanced risk assessment models are evolving to provide patients with clearer insights into their long-term health.
How Might a Novel Radioenhancer Impact Stage III Unresectable NSCLC Care?
JNJ-1900, an investigational nanoparticle radioenhancer, represents a “fantastic opportunity” to improve the standard of care in stage III unresectable non–small cell lung cancer (NSCLC), according to Benjamin Cooper, MD.
What Role Will The EV-304 Regimen Occupy in The Bladder Cancer Paradigm?
In the latest episode of Oncology Decoded, hosts Manojkumar Bupathi, MD, MS; and Benjamin Garmezy, MD, spoke about the clinical utility of enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) for those with muscle-invasive bladder cancer (MIBC) and similar patient populations.
Intensity-Modulated Radiation, Proton Therapy Show Similar OPSCC Outcomes
Intensity-modulated radiation therapy (IMRT) conferred similar outcomes vs intensity-modulated proton therapy (IMPT) among patients with locally advanced oropharyngeal squamous cell carcinoma (OPSCC), according to findings from the phase 3 TORPEdO trial (NCT01893307) published in The Lancet.
The Rise of Early-Onset Cancers: Investigating Breast and CRC Occurrences
The American Cancer Society’s annual cancer statistics report highlighted that, in 2025, 2,041,910 new cancer cases and 618,120 cancer deaths were projected to occur.1 Though there is a single name for the disease—cancer—there are hundreds of subtypes. Among them, 2 of the most common are breast and colorectal cancer (CRC), and unfortunately, they are on the rise in patients younger than 50.
Novel KRAS G12D-Targeted Agent Shows Early Activity in KRAS+ NSCLC
Early activity and tolerability were observed among patients who received setidegrasib, an investigational KRAS G12D-targeted protein degrader, for non–small cell lung cancer (NSCLC) harboring KRAS G12D mutations, according to data from a phase 1 trial presented at the 2026 European Lung Cancer Congress (ELCC) and published in The New England Journal of Medicine.1,2 The study’s primary end point was safety, with secondary end points of overall response rate (ORR), disease control rate, and...
Durvalumab/SBRT May Limit Tumor Progression in Early-Stage NSCLC
Combining durvalumab (Imfinzi) with stereotactic body radiotherapy (SBRT) appeared to reduce tumor progression among patients with early-stage non–small cell lung cancer (NSCLC), although the value of adjuvant immunotherapy in this population remains uncertain, according to findings from the phase 2 ASTEROID trial (NCT03446547) presented at the European Lung Cancer Congress 2026.1 Efficacy Results of Durvalumab/SBRT Regarding time to progression, investigators noted progression in 10 patients...
CSF Liquid Biopsy Displays 82% Clinical Impact in CNS Lymphoma
Summit™ and Vantage™, cerebrospinal fluid (CSF) liquid biopsies, displayed a clinically meaningful impact in 82% of central nervous system lymphoma (CNSL) cases, according to findings from a retrospective analysis including 50 CSF samples and 48 patients published in Lymphatics.1 Specifically, the Summit test detected significant variants, by gene level alteration, chromosomal arm level alteration, and/or MGMT promoter methylation per Tier 1 or 2 classification per AMP/ASCO/CAP guidelines, in...
Adjuvant Atezolizumab/mFOLFOX6 Improves DFS in Stage III dMMR Colon Cancer
Atezolizumab (Tecentriq) plus mFOLFOX6 (fluorouracil, oxaliplatin, leucovorin) significantly improved disease-free survival (DFS) compared with mFOLFOX6 alone in patients with stage III mismatch repair-deficient (dMMR) colon cancer, according to findings from the phase 3 ATOMIC trial (NCT02912559) published in The New England Journal of Medicine and reported by the Alliance for Clinical Trials in Oncology.1,2 This study represents the first phase 3 trial to evaluate the addition of an immune...
Novel Small Molecule Earns FDA Fast Track Designation in ALK+ NSCLC
The FDA has granted fast track designation to TRI-611, an investigational molecular glue degrader therapy, as a treatment for those with ALK-positive non–small cell lung cancer (NSCLC), according to a press release from the developer, TRIANA Biomedicines, Inc.1 Developers engineered TRI-611 as an orally available investigational agent that targets ALK fusion proteins among patients with NSCLC.
Teclistamab Combo Approval Affirms Role of Anti-BCMA Therapy in Myeloma
Teclistamab-cqyv (Tecvayli) plus daratumumab and hyaluronidase-fihj (Darzalex Faspro) has produced some of the “most exciting data” observed in relapsed/refractory multiple myeloma, according to María-Victoria Mateos, MD, PhD. In a conversation with CancerNetwork® following the FDA approval of teclistamab/daratumumab among those with relapsed/refractory multiple myeloma, Mateos described the clinical implications of this combination becoming available for patients.
How Will Data From ASCO GU 2026 Impact the Treatment Paradigm?
Following the 2026 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, Oncology Decoded hosts Manojkumar Bupathi, MD, MS; and Benjamin Garmezy, MD, met to break down the key trials and presentations that may help move the needle in genitourinary oncology. Together, they reviewed findings and clinical implications across various bladder cancer, kidney cancer, and prostate cancer populations.
The Evolution of Artificial Intelligence in Oncology: Impact on Trials, Workflows, and Outcomes
Artificial intelligence (AI) has been utilized in a variety of capacities to fundamentally transform oncology care since its inception. Technology that initially started out as a “hallucination-prone punch line” per Matthew Matasar, MD, chief of the Division of Blood Disorders at Rutgers Cancer Institute and Cancer Survivorship editorial advisory board member for ONCOLOGY, has since evolved into an “increasingly serious” facet of oncology care with a myriad of applications.
ASCO Genitourinary Cancers Symposium
ByManojkumar Bupathi, MD, MS,Benjamin Garmezy, MD Experts detail presentations that may influence the standard of care across different bladder, kidney, and prostate cancer populations. ByPablo Barrios, MD,Mustafa Saleh, MD Two genitourinary oncologists discussed research examining germline platelet polygenic risk scores to predict survival outcomes in kidney cancer.
CancerNetwork
Feb 28, 2026News The Technical Risks of Faster Radiation Treatments in Breast Cancer 2 hours ago Defining a New Standard of Care in the OPSCC Treatment Paradigm a day ago by Jason K. Molitoris, MD, PhD Managing Immunotherapy-Related Toxicities in Breast Cancer a day ago Orca-T Reduces the “Costs” of Transplantation in Blood Cancers 2 days ago Trial in Rare Leukemia Shows “Unprecedented Result” With Blinatumomab 3 days ago Can Preoperative Radiation Help Patients Skip Breast Cancer Surgery?
Olaparib Combo Improves PFS/OS in BRCA+ or ATM+ Metastatic CRPC | CancerNetwork
Combining olaparib (Lynparza) with abiraterone acetate (Zytiga) and prednisone improved efficacy outcomes such as progression-free survival (PFS) and overall survival (OS) vs each agent given alone or sequentially among those with metastatic castration-resistant prostate cancer (mCRPC) harboring BRCA1/2 or ATM alterations, according to data from the phase 2 BRCAAway trial (NCT03012321) presented at the 2026 ASCO Genitourinary Cancer Symposium.1 A total of 165 eligible patients were registered...
Community Centers vs Large Institutions: Discussing Differences in Care and Costs
Cancer is almost always an expensive disease, regardless of disease type, treatment type, or location of treatment. That does not mean that there are no differences between those categories, with regard to the location of treatment. Loretta Nastoupil, MD, discussed how these factors affect the costs of treatment.
Developer Terminates DHX9 Inhibitor Trial Amid Safety Concerns
Accent Therapeutics has terminated the development of its lead solid tumor candidate, ATX-559, following the emergence of a concerning adverse event profile in a phase 1/2 clinical trial (NCT06625515), according to a report from Fierce Biotech.1 ATX-559, an oral inhibitor of the DHX9 enzyme, was being investigated as a treatment for patients with advanced or metastatic BRCA1/2-deficient breast cancer or microsatellite instability–high (MSI-H) or deficient mismatch repair (dMMR) solid tumors.
Iza-bren Yields Statistically Significant Efficacy in Advanced TNBC
Statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) were noted with izalontamab brengitecan (iza-bren) for patients with unresectable locally advanced or metastatic triple-negative breast cancer with disease progression after prior taxane therapy, according to a press release from Bristol Myers Squibb.1 Iza-bren was assessed in in the phase 3 BL-B01D1-307 trial (NCT06382142), with these results being reported at the...
Decoding Key Community Oncology Takeaways From ASCO GI 2026
In the latest episode of Oncology Decoded, hosts Manojkumar Bupathi, MD, MS; and Benjamin Garmezy, MD, convened with Meredith Pelster, MD, MSCI; and Jason Henry, MD. Together, they looked back at the presentations and data shared at the 2026 ASCO Gastrointestinal Cancers Symposium that may have long-term impacts on community oncology practice across different gastrointestinal (GI) malignancies, including pancreatic cancer and colorectal cancer (CRC).
Meredith Pelster, MD, MSCI
Meredith Pelster, MD, MSCI Articles by Meredith Pelster, MD, MSCI Experts review potential clinical advances highlighted at the 2026 ASCO Gastrointestinal Cancers Symposium.
Eliminating Bias and Ethically Integrating AI for Palliative Oncology Care
Ram Prakash Thirugnanasambandam, MBBS, spoke with CancerNetwork® about considerations for responsibly using artificial intelligence (AI)–based tools in palliative medicine and the treatment of patients with hematologic malignancies. He discussed these strategies in the context of a manuscript he authored and published in the November/December 2025 issue of the journal ONCOLOGY®.
Leveraging Human Nuance in the AI Era of Radiation Oncology
As artificial intelligence (AI) and automated workflows rapidly redefine the technical landscape of radiation oncology, the role of the clinician is shifting from primary data processor to expert interpreter. Although AI tools offer unprecedented efficiency, they often lack the real-time clinical nuance derived from direct patient interaction. During the 2026 American College of Radiation Oncology (ACRO) Summit, CancerNetwork® sat down with Sunil W.
Highlighting Emerging Technologies in CNS Radiation Oncology
At the 2026 American College of Radiation Oncology (ACRO) Summit, Charlotte Ivy Rivers, MD, a radiation oncologist at the Medical University of South Carolina, served as the moderator for the Central Nervous System (CNS) traditional session. The session highlighted critical developments in the management of rare brain tumors, the integration of molecular biomarkers, and the expanding role of functional radiosurgery in treating benign conditions.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Manojkumar
Contact Manojkumar, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack